Peptides›Healing›PDA (Pentadeca-Arginate)

PDA (Pentadeca-Arginate)

/ Arginate salt formulation of the BPC-157 pentadecapeptide sequence

TIER 3 · PreclinicalN = 0 · TESTING PENDING

ALIAS · Pentadeca-Arginate · BPC-157 arginate salt · PDA peptide

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequenceGEPPPGKPADDAGLV (with arginate counter-ion)

MW · —CLASS · Arginate salt formulation of the BPC-157 pentadecapeptide sequenceCATEGORY · Healing

Tier 3 by component inheritance. PDA is the arginate salt of the BPC-157 pentadecapeptide sequence, marketed as a separate product with claims of improved stability and bioavailability. The BPC-157 base sequence has the rodent literature reviewed elsewhere (single-lab dominant); the arginate salt itself has no published characterisation distinct from the parent.

§ B · Mechanism of action

The active sequence is identical to BPC-157 — see the BPC-157 reference for proposed mechanisms (angiogenesis, growth-factor expression, NO modulation). The arginate counter-ion is intended to improve solubility and stability of the lyophilised product but has no published mechanistic role in pharmacology.

§ C · Human clinical evidence

None for PDA specifically. All clinical and preclinical evidence cited for PDA is by reference to the BPC-157 base molecule. The single-lab-dominance flag on BPC-157 (Sikiric group) carries through directly.

§ D · Primary literature

PubMed21548867Sikiric P et al. — Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract · Current Pharmaceutical Design · reviewTwenty-year review of BPC-157 preclinical literature, predominantly from one investigator group: GI ulcer healing, tendon and ligament repair, NSAID protection, dopaminergic effects.Limitations: Single-lab dominance — vast majority of cited primary studies authored by Sikiric's group at University of Zagreb; no Western replication of central findings; no human RCT data.2011

§ F · Safety signal

No PDA-specific safety database. BPC-157 base molecule has no formal Phase 1 human safety study.

§ H · Regulatory status

Regulatory status

FDA status:: Not FDA-approved

§ I · Notable gaps and controversies

The arginate-salt rebrand is a marketing repositioning rather than a chemically distinct molecule with its own data. Pricing and product positioning sometimes imply PDA is a 'next-generation' BPC-157; the published record does not support that framing.